Participated · Series A · May 2026

Tessera Labs develops autonomous AI agents trained to manage end-to-end enterprise IT and ERP transformations, including business-process design and automated code reconfiguration for large-scale system updates. Founder Kabir Nagrecha, who previously researched AI at Meta and Netflix, started the company after observing inefficiencies in traditional system-integrator models. Tessera says its approach can reduce the number of required consultants dramatically (from hundreds to a handful) and shorten coding cycles from around ten months to weeks. The company reports client-level savings exceeding $100 million annually for large enterprises and is working directly with customers such as Merck and Xerox while running trials with other Fortune 500 firms. Publicly reported metrics and financials beyond those claims were not provided in the articles.

Participated · Series C · Apr 2026

Terremoto Biosciences is a clinical-stage biotech company focused on designing highly selective, potent small-molecule AKT1 inhibitors. Its lead oncology program, TER-2013, is in Phase 1 clinical development for solid tumors harboring PIK3CA, AKT, or PTEN alterations. The company is also advancing TER-4480 for hereditary hemorrhagic telangiectasia, with clinical entry expected later this year. Terremoto emphasizes AKT1 selectivity to maximize efficacy while minimizing toxicities associated with AKT2 or PI3Kα inhibition. It is privately held and supported by investors including OrbiMed, Third Rock Ventures, Novo Holdings, Cormorant Asset Management, RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines. Terremoto is based in South San Francisco and San Diego.

Participated · Series B · Jan 2026

Precede Biosciences is a precision diagnostics and data company that has built a proprietary, automated assay capable of extracting high-resolution, genome-wide transcriptional information from a single blood draw. The platform integrates this assay with advanced machine-learning analytics, enabling researchers and clinicians to profile target expression and pathway activity—critical biomarkers for drug-, radio- and immune-conjugates and other targeted therapies. By providing a multiplex, minimally invasive alternative to tissue biopsies, the company aims to accelerate drug development and ensure patients receive therapies precisely matched to their disease biology. Current commercial traction is described as “rapidly growing,” driven by partnerships with developers of next-generation precision medicines. The fresh financing brings Precede Bio’s total new capital to $83.5 million, giving the company resources to scale its platform and meet rising demand. An expanded investor base with deep diagnostics-commercialization expertise is expected to support health-system adoption and long-term growth.

Participated · Series B · Jan 2026

Nocion Therapeutics is advancing taplucainium (formerly NTX-1175), a first-in-class, once-daily dry-powder inhaled charged sodium channel blocker (CSCB) that selectively silences activated airway nociceptors while minimizing systemic exposure. The company positions taplucainium as a potentially best-in-class therapy for the roughly nine million U.S. patients suffering from refractory or unexplained chronic cough, a field with no new FDA-approved drugs in 65 years. Taplucainium is currently being evaluated in the ASPIRE Phase 2b trial enrolling patients across the U.S., Canada, the U.K., and Europe, with topline data expected in mid-2026. Proceeds from the latest financing will fund trial completion, an End-of-Phase 2 meeting, and CMC work in preparation for late-stage studies, giving Nocion an operating runway through 2027. Beyond cough, the company’s CSCB platform may be applied to other conditions involving activated sensory neurons such as itch and pain. Nocion is headquartered in Watertown, Massachusetts, and was founded on intellectual property licensed from Harvard University and Boston Children’s Hospital. To date, the company has raised $93 million in Series B funding, including the recent extension.

Participated · Equity · Dec 2025

Addition Therapeutics is a spin-out from Professor Kathleen Collins’ laboratory at the University of California that focuses on an all-RNA, non-viral lipid nanoparticle (LNP) PRINT delivery platform. The technology is designed to produce "PRINTed" therapeutics targeting both chronic and rare diseases. Initial disease-related non-human primate studies are scheduled for 2026 as the company advances its preclinical pipeline. The company is led by CEO Ron Park, M.D., with a leadership team that includes CSO Francine Gregoire, CBO Priya Parameswaran, and other senior executives across operations, IP, and culture. Addition plans to deploy its latest capital to expand operations and scale R&D programs. To date, the company has secured $100 million in external financing, though no revenue or user metrics were disclosed in the article.